Compare · RVMD vs SLXN
RVMD vs SLXN
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $35.25B, about 12280.7x SLXN ($2.9M).
- Over the past year, RVMD is up 322.6% and SLXN is down 97.7% - RVMD leads by 420.3 points.
- RVMD has been more active in the news (15 items in the past 4 weeks vs 10 for SLXN).
- RVMD has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- Revolution Medicines Inc.
- Silexion Therapeutics Corp
- Price
- $169.21+2.06%
- $2.81-2.93%
- Market cap
- $35.25B
- $2.9M
- 1M return
- +10.02%
- -41.57%
- 1Y return
- +322.58%
- -97.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 15
- 10
- Recent ratings
- 25
- 0
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest RVMD
- Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
- Officer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax
- Officer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax
- General Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax
- Officer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Revolution Medicines Inc.
Latest SLXN
- Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- SEC Form EFFECT filed by Silexion Therapeutics Corp
- SEC Form 424B3 filed by Silexion Therapeutics Corp
- SEC Form DEF 14A filed by Silexion Therapeutics Corp
- Silexion Therapeutics to Attend BIO International Convention 2026
- SEC Form S-3 filed by Silexion Therapeutics Corp
- CSO and CDO Shirvan Mitchell was granted 6,000 units of Ordinary Shares, increasing direct ownership by 215% to 8,789 units (SEC Form 4)
- CFO and Secretary Horenshtein Hadar Mirit was granted 7,500 units of Ordinary Shares, increasing direct ownership by 150% to 12,515 units (SEC Form 4)
- Chairman and CEO Hadar Ilan was granted 10,000 units of Ordinary Shares, increasing direct ownership by 153% to 16,547 units (SEC Form 4)
- SEC Form PRE 14A filed by Silexion Therapeutics Corp